Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shot up 8.9% during trading on Thursday . The company traded as high as $0.40 and last traded at $0.3877. Approximately 6,543 shares changed hands during mid-day trading, an increase of 15% from the average session volume of 5,685 shares. The stock had previously closed at $0.3560.
Avenue Therapeutics Price Performance
The firm has a market cap of $1.28 million, a P/E ratio of 0.02 and a beta of -0.17. The company’s 50-day moving average is $0.31 and its two-hundred day moving average is $0.34.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
See Also
- Five stocks we like better than Avenue Therapeutics
- Microsoft Just Flipped the AI Spending Narrative Overnight
- Qualcomm’s Turnaround Is Working, So Why Is Wall Street Selling?
- Meta’s Earnings Show Why Wall Street Is Losing Patience With AI Spending
- Can Starbucks Keep This Turnaround Going? The Latest Results Say Yes
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
